Lyell Immunopharma Inc [NASDAQ: LYEL] stock went on a downward path that fall over -36.03% on Wednesday, amounting to a one-week price decrease of less than -37.86%.
Over the last 12 months, LYEL stock dropped by -59.22%. The one-year Lyell Immunopharma Inc stock forecast points to a potential upside of 82.67. The average equity rating for LYEL stock is currently 1.67, trading closer to a bullish pattern in the stock market.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The market cap for the stock reached $332.70 million, with 253.96 million shares outstanding and 118.69 million shares in the current float. Compared to the average trading volume of 797.91K shares, LYEL stock reached a trading volume of 11856879 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Lyell Immunopharma Inc [LYEL]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for LYEL shares is $7.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on LYEL stock is a recommendation set at 1.67. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
JP Morgan have made an estimate for Lyell Immunopharma Inc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on August 28, 2023. While these analysts kept the previous recommendation, Morgan Stanley raised their target price from $15 to $7. The new note on the price target was released on November 14, 2022, representing the official price target for Lyell Immunopharma Inc stock. Previously, the target price had yet another drop from $13 to $7, while Goldman kept a Neutral rating on LYEL stock.
The Average True Range (ATR) for Lyell Immunopharma Inc is set at 0.22, with the Price to Sales ratio for LYEL stock in the period of the last 12 months amounting to 4752.81. The Price to Book ratio for the last quarter was 0.55, with the Price to Cash per share for the same quarter was set at 2.06.
LYEL Stock Performance Analysis:
Lyell Immunopharma Inc [LYEL] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -37.86. With this latest performance, LYEL shares dropped by -52.89% in over the last four-week period, additionally sinking by -38.44% over the last 6 months – not to mention a drop of -59.22% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for LYEL stock in for the last two-week period is set at 23.43, with the RSI for the last a single of trading hit 16.03, and the three-weeks RSI is set at 29.46 for Lyell Immunopharma Inc [LYEL]. The present Moving Average for the last 50 days of trading for this stock 2.43, while it was recorded at 1.92 for the last single week of trading, and 2.08 for the last 200 days.
Insight into Lyell Immunopharma Inc Fundamentals:
Lyell Immunopharma Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 16.51 and a Current Ratio set at 16.51.
LYEL Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for LYEL. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Lyell Immunopharma Inc go to -7.90%.
Lyell Immunopharma Inc [LYEL] Institutonal Ownership Details
The top three institutional holders of LYEL stocks are: VANGUARD GROUP INC with ownership of 1.32 billion shares, which is approximately 8.4983%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $200.69 billion in LYEL stocks shares; and BERKSHIRE HATHAWAY INC, currently with $174.35 billion in LYEL stock with ownership which is approximately 5.8386%.
